Spyryx Biosciences: About Us

Spyryx Biosciences is pioneering the use of inhaled peptides to treat severe pulmonary diseases where mucus accumulation and obstructions are key to disease progression. Our compounds have a novel mechanism of action that removes epithelial sodium channels from the airway surface with the therapeutic goal of increasing airway hydration and mucus clearance to enhance lung performance. Spyryx’s lead program, SPX-101, is in Phase 2 testing for CF.